Morpholino

MO1-mir26a

ID

ZDB-MRPHLNO-200609-1

Name

MO1-mir26a

Previous Names

None

Targets

Sequence

5' - AGCCTATCCTGGATTACTTGAAC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-mir26a

Expressed Gene	Anatomy	Figures
acta2	head pharyngeal arch ventral region	Fig 5 , Fig. S5 from Watterston et al., 2019
myh11a	head pharyngeal arch ventral region	Fig 5 , Fig. S5 from Watterston et al., 2019
notch3	head	Fig 5 from Watterston et al., 2019
pdgfba	head	Fig 5 from Watterston et al., 2019
pdgfrb	head	Fig 5 from Watterston et al., 2019
smad1	aortic arch head pharyngeal arch ventral region ventral aorta whole organism	Fig 2 , Fig. S4 from Watterston et al., 2019

Phenotype

Phenotype resulting from MO1-mir26a

No data available

Phenotype of all Fish created by or utilizing MO1-mir26a

Phenotype	Fish	Conditions	Figures
whole organism smad1 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 2 from Watterston et al., 2019
head myh11a expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
head notch3 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
pharyngeal arch ventral region smad1 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 2 from Watterston et al., 2019
head acta2 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
head pdgfrb expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
ventral aorta smad1 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 2 from Watterston et al., 2019
aortic arch smad1 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 2 from Watterston et al., 2019
head smad1 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 2 , Fig. S4 from Watterston et al., 2019
head hemorrhagic, abnormal	WT + MO1-mir26a	control	Fig 4 , Fig. S4 from Watterston et al., 2019
pharyngeal arch ventral region myh11a expression increased amount, abnormal	WT + MO1-mir26a	control	Fig. S5 from Watterston et al., 2019
head pdgfba expression increased amount, abnormal	WT + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
pharyngeal arch ventral region acta2 expression increased amount, abnormal	WT + MO1-mir26a	control	Fig. S5 from Watterston et al., 2019
whole organism ventralized, ameliorated	WT + MO1-mir26a + MO1-smad1	control	Fig 4 from Watterston et al., 2019
head hemorrhagic, ameliorated	WT + MO1-mir26a + MO1-smad1	control	Fig 4 from Watterston et al., 2019
ventral aorta endothelial cell decreased amount, ameliorated	y7Tg + MO1-mir26a	chemical treatment by environment: inhibitor	Fig 6 from Watterston et al., 2019
ventral aorta vascular smooth muscle amount, ameliorated	ca7Tg; ci5Tg + MO1-mir26a	chemical treatment by environment: inhibitor	Fig 6 from Watterston et al., 2019
ventral aorta length, ameliorated	ca7Tg; ci5Tg + MO1-mir26a	chemical treatment by environment: inhibitor	Fig 6 from Watterston et al., 2019
aortic arch vascular smooth muscle amount, ameliorated	ca7Tg; ci5Tg + MO1-mir26a	chemical treatment by environment: inhibitor	Fig 6 from Watterston et al., 2019
ventral aorta vascular smooth muscle decreased height, abnormal	ca8Tg; mw29Tg + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
ventral aorta vascular smooth muscle increased amount, abnormal	ca8Tg; mw29Tg + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
aortic arch EGFP expression increased amount, abnormal	ca8Tg; mw29Tg + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
aortic arch vascular smooth muscle increased amount, abnormal	ca8Tg; mw29Tg + MO1-mir26a	control	Fig 5 from Watterston et al., 2019
aortic arch vascular smooth muscle decreased height, abnormal	ca8Tg; mw29Tg + MO1-mir26a	control	Fig 5 from Watterston et al., 2019

Citations